Raymond James raises Lexeo Therapeutics price target on trial data

Raymond James raised Lexeo Therapeutics' (LXEO) price target to $42 from $24, citing positive trial data. The stock is down 71% YTD. The firm noted an 80% reduction in non-sustained ventricular tachycardia and a 44% reduction in premature ventricular contractions in high-dose patients. Lexeo also completed its acquisition of Mantle Therapeutics for $5.3M in cash and $3M in stock. Other analysts maintain positive ratings with targets ranging from $17 to $35.

Original reporting
Published Nov 16, 2026, 1:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 1:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$LXEO
Bullish
high confidence
Mentioned
$LXEO
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$LXEOBullishMed
01

Why it matters

The upgraded target reflects belief that the trial data de‑risk the program and could accelerate partnership or licensing opportunities.

02

Market read

New data and analyst upgrade may drive short‑term price appreciation for LXEO.

03

What to watch

Regulatory timeline and next‑stage trial funding requirements.

Relevance 8/10Novelty 8/10Timing: today

Background

Lexeo Therapeutics is a clinical‑stage biotech developing gene‑therapy for PKP2‑associated cardiomyopathy.

Company-level read

Ticker impact

$LXEOBullishHigh confidence
Context

Raymond James raised its price target to $42 after 12‑month trial data showed 80% reduction in VT episodes, indicating strong clinical progress.

Expected impact

likely upward move as investors price in improved efficacy and higher target

Evidence & confidence

Analyst upgrade based on hard data; market typically reacts positively to late‑stage biotech data.

Market effects

Strengthens outlook for rare‑disease gene‑therapy sector.

US biotech investors may see increased risk‑on sentiment.

Limited to biotech niche, no broad market effect.

Counterpoint

Cash burn remains high; small patient cohort may limit confidence.

Key entities

  • Raymond James

    Raised price target to $42, maintains Strong Buy.

  • Lexeo Therapeutics

    Reported 12‑month follow‑up data from HEROICPKP2 trial.

Related articles

$LXEOMedAI 8/10

Lexeo Therapeutics Stock Jumps 12% On Positive Gene Therapy Data

Lexeo Therapeutics (LXEO) stock rose 12% after positive interim results from its Phase I/II HEROIC-PKP2 study of LX2020, a gene therapy for PKP2 arrhythmogenic cardiomyopathy. The therapy reduced non-sustained ventricular tachycardia by 80% and premature ventricular contractions by 44% in high-dose patients. The company reported a Q3 net loss of $38.3 million, up from $20.3 million last year, with R&D expenses increasing to $34.5 million.

$LXEOHighAI 9/10

Why is Lexeo Therapeutics stock surging today?

Lexeo Therapeutics (LXEO) stock rose 23.7% in pre-market trading after reporting positive interim data from its HEROIC-PKP2 trial for LX2020, showing 80% reduction in NSVT. The FDA indicated openness to using NSVT as a surrogate endpoint. Analysts raised price targets, with Raymond James increasing to $42. The company reported $219.1M in cash, funding operations into 2028, despite a Q3 net loss of $38.3M.